Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes

American Journal of the Medical Sciences

Volumn 334, Issue 6, 2007, Pages 466-480

  Palumbo, Pasquale J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diabetes mellitus; Endothelial dysfunction; Erectile dysfunction; Metabolic risk factors; PDE5 inhibitors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL; VASODILATOR AGENT;

ABDOMINAL OBESITY; ALCOHOL ABSTINENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HEART INFARCTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISCHEMIC OPTIC NEUROPATHY; LIFESTYLE MODIFICATION; MEDICAL LITERATURE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PENIS PROSTHESIS; PRACTICE GUIDELINE; PREVALENCE; PSYCHOTHERAPY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SMOKING CESSATION; TRANSIENT GLOBAL AMNESIA; VASCULAR ENDOTHELIUM; VASODILATATION;

CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; PHOSPHODIESTERASE INHIBITORS; RISK FACTORS;

EID: 37349045734     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318126c198     Document Type: Review

References (90)

1. Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60:458-65.
2. Benvenuti F, Boncinelli L, Vignoli GC. Male sexual impotence in diabetes mellitus: vasculogenic versus neurogenic factors. Neurourol Urodyn 1993;12:145-51.
3. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12:59-66.
4. Christ GJ, Maayani S, Valcic M, et al. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol 1990;101:375-81.
5. Kaiser FE, Viosca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36:511-9.
6. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: Impotence. JAMA 1993;270:83-90.
7. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
8. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6.
9. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2003.
10. Sarica K, Arikan N, Serel A, et al. Multidisciplinary evaluation of diabetic impotence. Eur Urol 1994;26:314-8.
11. Metro MJ, Broderick GA. Diabetes and vascular impotence: does insulin dependence increase the relative severity? Int J Impot Res 1999;11:87-9.
12. Hatzichristou D, Seftel A, Saenz de Tejada I. Sexual dysfunction in diabetes and other autonomic neuropathies. In: Singer C, Weiner WJ, eds. Sexual dysfunction: a neuromedical approach. Armonk, NY: Futura; 1994.
13. Guay AT, Bansal TB, Jacobson JJ, et al. Does erectile dysfunction foreshadow cardiac disease? Incidence of metabolic syndrome and insulin resistance in an ED population (Abstract MP48). J Urol 2004;171(Suppl 1):75-6.
14. Romeo JH, Seftel AD, Madhun ZT, et al. Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000;163:788-91.
15. Matfin G, Jawa A, Fonseca VA. Erectile dysfunction: interrelationship with the metabolic syndrome. Curr Diab Rep 2005;5:64-9.
16. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001;24:1936-40.
17. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004;43:1405-11.
18. Esposito K, Giugliano F, Martedi E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005;28:1201-3.
19. Gunduz MI, Gumus BH, Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. Asian J Androl 2004;6:355-8.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
21. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996;93:210-4.
22. Furchgott RF, Zawadzki IV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
23. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
24. De Angelis L, Marfella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 2001;44:1155-60.
25. Foresta C, Lana A, Cabrelle A, et al. PDE-5 inhibitors, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 2005;17:377-80.
26. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74.
27. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
28. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004;43:179-84.
29. Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006;18:55-60.
30. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004;171:2341-5.
31. Bocchio M, Desideri G, Scarpelli P, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 2004;171:1601-4.
32. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-4.
33. Greenstein A, Chen J, Miller H, et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997;9:123-6.
34. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004;110:22-6.
35. Blumentals WA, Gomez-Caminero A, Joo S, et al. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004;16:350-3.
36. Hakim J, Subit M, Kandzari S, et al. Quality control in the screening of erectile dysfunction: results of a survey. Urology 2002;60:125-9.
37. Fisher WA, Meryn S, Sand M, et al. Communication about erectile dysfunction among men with ED, partners of men with ED, and physicians: the Strike Up a Conversation Study (Part 1). J Men Health Gender 2005;2:64-78.
38. Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 2003;15:87-9.
39. Ward RA, Raiche P, Fidler HM. Results of a national needs assessment for continuing medical education of family physicians related to erectile dysfunction and/or male sexual dysfunction. J Sex Reprod Med 2002;2:55-60.
40. American Urological Association. Management of erectile dysfunction: American Urological Association (AUA) Education and Research, 2005. Linthicum, MD: American Urological Association; 2005.
41. Risen CB. A guide to taking a sexual history. Psychiatr Chin North Am 1995;18:39-53.
42. AACE Male Sexual Dysfunction Task Force, Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem: 2003 update. American Association of Clinical Endocrinologists; 2003. Jacksonville, FL: American Association of Clinical Endocrinologists; 2003.
43. AACE Hypogonadism Task Force, Petak SM, Nankin HR, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2003 update: American Association of Clinical Endocrinologists; 2003. Jacksonville, FL: American Association of Clinical Endocrinologists; 2003.
44. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21.
45. Jackson G, Rosen RC, Kloner RA, et al. The second Princeton consensus on sexual dysfunction and cardiovascular risk: new guidelines for sexual medicine. J Sex Med 2006;3:28-36.
46. Chobanian AV, Bakris GL, Black HR, et al, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
47. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36.
48. Brunner H, Cockcroft JR, Deanfield J, et al, for the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases: a statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-46.
49. Corona G, Mannucci E, Petrone L, et al. Psychobiological correlates of smoking in patients with erectile dysfunction. Int J Impot Res 2005;17:527-34.
50. de Boer BJ, Bots ML, Lycklama a Nijeholt AA, et al. Erectile dysfunction in primary care: prevalence and patient characteristics: the ENIGMA study. Int J Impot Res 2004;16:358-64.
51. Corbin JD, Francis SH. Pharmacology ofphosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9.
52. Viagra® sildenafil citrate[package insert]. Viagra. New York, NY: Pfizer, Inc; 2005.
53. Cialis® tadalafil [package insert]. Cialis. Indianapolis, IN: Eli Lilly and Company; 2005.
54. Levitra® vardenafil HC1 [package insert]. Levitra. West Haven, CT/Research Triangle Park, NC/Kenilworth, NJ: Bayer Healthcare, GlaxoSmithKline, and Schering-Plough Corporation; 2005.
55. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
56. Boulton AJ, Selam JL, Sweeney M, et al. Sildenafil citrate for the treatment of erectile dysfunction in men with type 2 diabetes mellitus. Diabetalogia 2001;44:1296-301.
57. Stuckey BG, Jadzinsky MN, Murphy U, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of randomized controlled trial. Diabetes Care 2003;26:279-84.
58. Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64.
59. Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23.
60. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
61. Ziegler D, Merfort F, Van Ahlen H, et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in type 1 diabetic patients with erectile dysfunction (Abstract 514-P). Diabetes 2005;54:A127.
62. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
63. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.
64. Porst H, Young IM, Schmidt AC, et al. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003;62:519-23.
65. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004;17:1135-42.
66. Aranda P, Ruilope LM, Calvo C, et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004;17:139-45.
67. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003;92:47M-57M.
68. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004;93:1276-81.
69. Padma-Nathan H, Porst H, Eardley I, et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Am J Hypertens 2002;15:48A.
70. van Ahlen H, Faich G, Morganroth J. Cardiovascular safety of the combination of vardenafil and alpha-blockers: a subgroup analysis of the post-marketing surveillance study 'real life safety and efficacy' of vardenafil (REALISE) (Abstract 734). J Urol 2005;173:200.
71. Goldstein I, Kim E, Steers WD, et al. High prevalence of significant comorbid conditions in men with erectile dysfunction: momentous trial demonstrates efficacy and safety of tadalafil in this group (Abstract 875). J Urol 2005;173:238.
72. Goldfischer E, Eardley I, Segerson T. Vardenafil improves erectile function in men with significant comorbidities association with erectile dysfunction (Abstract 714). J Urol 2002;167:178.
73. Arruda-Olson AM, Mahoney DW, Nebra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002;287:719-25.
74. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40:2006-12.
75. Gori T, Sicuro S, Dragoni S, et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005;111:742-6.
76. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20.
77. Galie N, Ghofrani HA, Torbicki A, et al, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
78. Caglayan E, Hunteburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166:231-3.
79. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003;108:239-44.
80. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92:37M-46M.
81. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003;92:26M-36M.
82. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005;96:443-6.
83. van Ahlen H, Wahle K, Kupper W, et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005;2:856-64.
84. Tomsak R. PDE5 inhibitors and permanent visual loss. Int J Impot Res 2005;17:547-9.
85. US Food and Drug Administration. FDA alert for healthcare professionals [vardenafil]: US FDA, 2005.
86. Gandolfo C, Sugo A, Del Sette M. Sildenafil and transient global amnesia. Neurol Sci 2003;24:145-6.
87. Savitz SA, Caplan LR. Transient global amnesia after sildenafil (Viagra) use. Neurology 2002;59:778.
88. Schiefer J, Sparing R. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association? Int J Impot Res 2005;17:383-4.
89. Stief C, Porst H, Saenz De Tejada I, et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004;58:230-9.
90. Sheu JY, Chen KK, Lin AT, et al. Long-term efficacy and safety of sildenafil for patients with erectile dysfunction. J Chin Med Assoc 2003;66:480-6.